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Abstract 
Background: Relatively large number of false-negative malaria rapid diagnostic test (RDT) results for microscopically 
confirmed Plasmodium falciparum cases were reported from five of the six administrative regions of Eritrea in 2015. 
This activated the Ministry of Health to conduct an initial exploratory investigation. The main objective of the inves-
tigation was to confirm the sensitivity of the RDTs in the field in microscopically confirmed malaria cases, identify the 
possible causes of the failure and recommend further actions to be taken.
Methods: A team composed of the National Malaria Control Programme, National Medicines and Food Administra-
tion and Laboratory Unit of the Ministry of Health was established to confirm the sensitivity of the SD Bioline® RDTs. 
A ‘Malaria RDT quality monitoring form’ was prepared and distributed to 13 health facilities selected on availability of 
microscopy services, experienced laboratory personnel and malaria endemicity, to carry out preliminary investiga-
tion on the suspected RDT quality defect. In parallel, field visits to central and regional medical warehouses as well as 
selected health facilities were conducted to assess the storage conditions, handling and operator procedures. Further-
more, joint field assessment was conducted with the manufacturer, SD Bioline RDTs. During the time frame of 15 July 
2015 to 19 January 2016, 65 microscopically confirmed patients were tested with Malaria RDTs SD Bioline Pf/Pv/Mixed 
Combo cassettes.
Results: A total of 65 blood specimens (50 P. falciparum, 13 Plasmodium vivax and 2 mixed) confirmed microscopi-
cally were tested against the available lots of malaria RDTs. Out of the 50 P. falciparum infected blood specimens, only 
10 were confirmed positive with all the lots of PfHRP-2 detecting RDTs making the false negativity rate at 80% [41/51]. 
The false negative result for RDT targeting PfHRP2 antigen ranged from 65% [11/17] in Gash Barka region to 100% 
[12/12] in Northern Red Sea Region. In addition, supervisory visits undertaken by the study team have ruled out stor-
age, handling and operator errors as causes of false negative results as the above parameter were found to be up to 
standards.
Conclusion: The investigation confirmed high false-negativity rate in PfHRP-2 detecting RDTs and has ruled out qual-
ity of RDTs, storage, handling and operator error as causes of the reported problem. Therefore, molecular characteriza-
tion of the P. falciparum is highly recommended to explore if parasite characteristics can be considered as causes of 
false negative results.
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Background
Eritrea is a country located in the Horn of Africa, 
where 67% of its inhabitants live in malaria risk areas 
[1]. Though, malaria was one of the main public health 
problems in the country, intensive control interven-
tions over the years, have resulted in marked decline in 
malaria cases and related deaths [2–4]. Integrated vector 
management, early diagnosis and treatment of malaria 
using parasitological confirmation at health facility and 
community levels were the main strategies deployed 
in the control of malaria. Based on the 2012 World 
Health Organization (WHO) malaria treatment guide-
lines [5], and the recommendation on malaria diagnosis 
in low-transmission settings [6], all suspected malaria 
cases were confirmed using microscopy or rapid diag-
nostic tests (RDTs). The use of microscopy in Eritrea is 
recommended for health facilities with laboratory ser-
vices mainly at health centres and hospitals, and RDTs 
at health stations and community level. For more than 
10  years, Eritrea has been using quality assured RDTs 
detecting Plasmodium antigens to diagnose malaria at 
health station level which gradually expanded to commu-
nity health agents and drug retail outlets. Based on the 
health facilities report, the dominant species in Eritrea 
are Plasmodium falciparum, accounting for 67% of the 
confirmed malaria cases, followed by Plasmodium vivax 
for the remaining 30% and with few proportions of mixed 
infections [7]. Based on this distribution, RDTs detecting 
histidine-rich protein 2 and Plasmodium lactate dehy-
drogenase (Pfhrp2/pLDH) have been deployed to ena-
ble health providers detect all locally prevalent malaria 
species.
In accordance to the recommendations, RDTs were 
deployed in 2007 following training of health workers. 
These have been used with very good results and mini-
mized the number of cases that were treated clinically 
at all levels and improved rational use of anti-malarial 
drugs. In the initial period, the type of RDTs that was 
deployed was of a P. falciparum-only type, which was 
later on replaced with tests detecting both P. falciparum 
and P. vivax. In most cases, the RDTs used were quality-
assured before shipment.
Starting from mid-2015, the National Malaria Control 
Programme and the Eritrean Pharmacovigilance Center 
received from health facilities reports of suspected qual-
ity defects on the WHO Prequalified RDTs (SD Bioline 
Pf/Pv/Mixed Combo cassettes) that had previously 
passed WHO-sponsored pre-shipment quality testing. 
The facilities reported failures of RDTs detecting micro-
scopically confirmed malaria cases. Initially there had 
been a few false-negative result complaints reported in 
late 2014, which were dismissed thinking that this could 
have been due to operator errors. However, in 2015, 
relatively large number of false-negative complaints from 
five of the six administrative regions activated the Minis-
try of Health to conduct initial investigation before con-
tacting the manufacturer.
The main objective of the investigation was to confirm 
the sensitivity of the RDTs in the field in microscopically 
confirmed malaria cases, identify the possible causes of 
the failure and recommend further actions to be taken. 
Capacity of microscopic diagnosis of suspected malaria 
patients is available at health centres and hospitals, which 
are medium level and highest level health care delivery 
facilities, respectively. Refresher training is conducted 
annually on malaria microscopy to enhance capacity of 
laboratory technologists. Moreover, regular internal and 
external quality control systems are in place with higher 
level facilities (selected regional hospitals) cross-checking 
blood films from lower level facilities while the National 
Health Laboratory (NHL) cross-checks highly discrep-
ant slides according to national guidelines. The NHL also 
participates in external quality control activities facili-
tated by NHLS/NICD based in South Africa. This paper 
focuses on the result of this investigation and the possible 
outcomes.
Methods
A team composed of the National Malaria Control Pro-
gramme (NMCP), National Medicines and Food Admin-
istration (NMFA) and Laboratory Unit of the Medical 
Services department was established to confirm the sen-
sitivity of the SD Bioline RDTs. The team jointly prepared 
a ‘Malaria RDT quality monitoring form’ and distributed 
it to 13 health facilities (distributed in four of the six 
administrative regions) selected on availability of micros-
copy services, experienced laboratory personnel and 
malaria endemicity, to carry out preliminary investiga-
tion on the suspected RDT quality defect.
In the time-period 15 July 2015 to 19 January 2016, all 
patients who presented to the facilities with signs and 
symptoms of malaria, irrespective of age and sex, were 
eligible for inclusion for the study. Eligible patients were 
finger pricked for preparation of thin and thick blood 
films. All microscopically confirmed malaria patients 
were again finger pricked and tested with Malaria 
HRP2/P.f. HRP2/pLDH (SD Bioline Malaria Ag Pf/Pv) 
RDTs. Every health facility was instructed to test every 
microscopically malaria confirmed specimen against 
all the available lots of RDTs. The laboratory technolo-
gists were also oriented to document all laboratory test 
results and report both the blood film (B/F) and RDT 
results to NMFA or NMCP with proper labeling in the 
provided format. Thick and thin blood films were pre-
pared and fixed with absolute methanol after which 
reading was conducted by expert microscopists. As part 
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of quality control mechanism, all malaria positive slides 
were sent to the National Health Laboratory for second 
reading focusing on parasite identification and parasite 
count. The data collected from the investigation sites 
using structured format were entered into an Excel sheet 
within NMCP Office. Direct analysis on range of parasi-
taemia, percentage of false negative results by species and 
investigation site or zone was conducted.
The team also conducted assessment on the storage, 
handling and usage of RDTs and their shipment his-
tory to exclude external factors that can affect the per-
formance. Moreover, to exclude environmental factors, 
15 lots of RDTs retained in the Central Medical Store 
(PHARMECOR—Eritrea), an ideal warehouse, were dis-
tributed to the 13 designated study sites (Fig. 1).
In addition to the local assessment, joint assessment 
was conducted in-country with SD Company delegates 
on two types of blood: positive control prepared by SD 
at 2000  parasites/µl and blood taken from five malaria 
patients in two Hospitals of the country. Four of the spec-
imens were fresh, while one was frozen for 3 days. In this 
joint assessment, four types of RDTs have been tested, 
namely SD Pf/Pv, SD Pf/Pan, CareStart® Pf/Pv and 
RAPID 1-2-3® Hema Cassette Malaria Pf/Pv (SD Bioline 
Malaria Ag Pf/Pv, SD, Bioline Malaria Ag Pf/Pa CareStart 
Malaria HRP2/PLDH (Pf/Pv) COMBO, and RAPID 1-2-
3® Hema Cassette Malaria PF/PV TEST, respectively) 
tests for comparative analysis. In addition, the SD Pf/Pv 
RDTs included those retained at SD Company (South 
Korea) and RDTs distributed to Eritrean health facilities.
Ethical considerations
Consent was taken from all patients to provide blood 
sample for investigation. All confirmed patients were 
treated for malaria based on the national malaria treat-
ment guideline.
Limitations
The investigation was conducted as rapid response to 
the complaints repeatedly reported from the field and 
hence, sample size was not properly determined and the 




Out of the 13 health facilities designated to monitor 
the quality of malaria RDTs, 12 facilities located in 
Fig. 1 Study sites
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four malarious regions of the country (Northern Red 
Sea, Anseba, Gash Barka & Debub) reported from 
which these data have been analysed. A total of 65 
blood specimens (50 P. falciparum, 13 P. vivax, and 2 
mixed) confirmed microscopically were collected and 
tested against the available lots of malaria RDTs. A 
total of 15 lots of RDTs were tested within the selected 
facilities.
The parasite density of the specimens ranged from 170 
to 84,000  asexual parasites/µl with geometric mean of 
10,094  parasites/µl. Out of the 50 microscopically con-
firmed P. falciparum infected blood specimens only 10 
were confirmed positive with all the lots of RDTs tested 
making the false negativity proportion at 80% (41/51) 
(Fig.  2). The false negativity result for PfHRP2 target 
antigen ranged from 61% (11/18) in Gash Barka region 
to 100% (12/12) in Northern Red Sea Region (Table  1). 
While the majority of P. falciparum infected blood speci-
mens turned false negative when tested with RDTs, out of 
13 P. vivax specimens only one tested false negative with 
RDTs. The P. vivax case that was false negative had low 
parasitaemia at 170/µl which could not be cross-checked 
at National Health Laboratory due to loss of the micro-
slide. The two mixed infections, as confirmed by micros-
copy, were tested positive (P. vivax) for the first mixed 
infection and negative for the second mixed infection 
when tested by RDTs. The above RDT results were con-
sistent across all lots of Pf/Pv (HRP/pLDH) RDTs tested 
at respective health facilities.
Joint assessment with the manufacturer
The joint assessment with the manufacturer of five P. fal-
ciparum patients yielded the following results. A known 
positive control, prepared at 2000 parasites/µl, gave posi-
tive results when tested against all SD Bioline HRP2Pf/
Pv RDTs whether they were retained with the manufac-
turer or those distributed to the field in Eritrea. However, 
the five malaria patients (all were microscopy confirmed 
P. falciparum-infected) could not be detected by all the 
RDTs, except with SD Pf/Pan type where the Pan-line 
band only turned positive to each of the specimens 
(Table  2). All the microscopically confirmed cases were 
also re-confirmed by PCR by SD at the manufacturing 
facility.
Fig. 2 Some of the false negative results of malaria RDTs
Table 1 Result of blood specimens tested microscopically and by RDT
Region P. falciparum P. vivax
Microscopically confirmed Negative with RDT % Microscopically confirmed Negative with RDT %
Northern Red Sea 12 12 100.0 0 0 0
Anseba 14 13 92.9 3 1 33
Gash Barka 17 11 64.7 8 0 0
Debub 7 5 71.4 2 0 0
50 41 80.4 13 1 7.7
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Storage and handling
The team confirmed that temperature monitoring chart, 
RDTs storage conditions, test procedures, performance 
of laboratory technologists were appropriate. Moreover, 
it was confirmed that the product was shipped to the 
country in refrigerated containers which were electrified 
during travel as well as ports of transit and destination.
Discussion
In Eritrea, RDTs have been the mainstay of malaria 
diagnosis in majority of health facilities and community 
health workers with no microscopy services. However, 
whenever three-quarters of the RDT tests fail to detect 
falciparum parasites, obviously it affects the confidence 
of health workers on this diagnostic method. Moreo-
ver, this has far reaching implications such as treating 
patients on clinical suspicion, threat of drug resistance, 
as well as possibility of missing a malaria case and con-
sequent complications and mortalities [8]. This observed 
failure is divergent from the WHO minimum selection 
criteria for malaria RDTs, i.e. Panel Detection Score 
(PDS) against P. falciparum samples should be at least 
75% at 200 parasites/µL [9].
Many factors affect the performance of RDTs starting 
from the quality of the product, its transportation, stor-
age and distribution to the skill of the operator [8, 10, 
11]. While the root cause analysis continues, findings of 
the initial investigation unambiguously highlighted that 
the suspected quality defect of the malaria RDTs or low 
parasite densities as cause to the false negativity are to be 
ruled out. This is evident from the fact that the product 
(SD Bioline Pf/Pv/Mixed Combo cassettes) was Prequali-
fied by WHO have passed WHO-sponsored pre-ship-
ment quality testing, have been shipped in refrigerated 
containers that were powered during shipment and ports 
of transit/destination and that local storage condition in 
the field were optimal.
The microscopy and PCR-confirmed P. falciparum 
samples were negative for P. falciparum test bands when 
examined with four similar types of RDTs (SD Pf/Pv, SD 
Pf/Pan, CareStart Pf/Pv and Rapid 1-2-3 Hema cassette 
malaria Pf/Pv test) showing that the problem was not 
limited to the SD Pf/Pv, but to all HRP-2 RDT brands. 
Neither SD Pf/Pv RDTs collected from the field nor those 
retained samples at SD Company resulted in positive 
bands for P. falciparum. However, the specimens tested 
positive for pan-line with SD Pf/Pan RDT, indicating 
that pLDH antigen has been detected. The P. falciparum 
samples that have been PCR-confirmed have also been 
shown to be negative for other plasmodium species as 
part of initial evidence and as recommended by Cheng 
et al. [12]. In addition, the false negative results for P. fal-
ciparum specimens occurred at low, medium and high 
parasite densities proving that parasitaemia did not influ-
ence the false negativity.
Besides to quality and handling of RDTs, parasite-
related factors such as absence of antigens detected by 
these RDTs are also implicated for poor performance 
[12–14]. Such absence of PfHRP2 genes from P. falcipa-
rum was the cause of high false negativity in the Amazo-
nian region of Peru [13], Mali [14] and recently in India 
[15]. The initial findings in this investigation i.e. negative 
result in all HRP-2 detecting RDT brands of three com-
panies but positive in the SD Pf/Pan may be a clue that 
Pfhrp2 antigen, which is the target for the P. falciparum 
band, might have been absent due to deletion of a gene 
that encodes the protein. Though, such type of gene dele-
tion is not reported in the East African region, further 
molecular study is recommended to confirm presence or 
absence of the genes to guide future actions in the coun-
try. This investigation has provided health care profes-
sionals and malaria control programme an insight into 
effectiveness of malaria RDTs in different settings and its 
implication on treatment of suspected malaria cases.
Conclusion
The currently prevailing situation of RDTs has certainly 
compromised malaria diagnosis and treatment in Eri-
trea, a country who has scored tremendous achievement 
in malaria control over the past 15 years. Analysis of the 
Table 2 Malaria patients and test results of different RDT types, Ghindae Hospital
Specimen Microscopy  
confirmation
SD Bioline HRP2Pf/
Pv (retained at SD 
company)










Positive control (2000 
Pf. parasites/µl
Confirmed by SD as 
Pf (by PCR)
Positive Positive Not tested Not tested Not tested
Patient 1 P. falciparum Negative Negative Positive Negative Negative
Patient 2 P. falciparum Negative Negative Positive Negative Negative
Patient 3 P. falciparum Negative Negative Positive Negative Negative
Patient 4 P. falciparum Negative Negative Positive Negative Negative
Patient 5 P. falciparum Negative Negative Positive Negative Negative
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initial investigation of RDTs failing to detect malaria 
parasites has ruled out quality of RDTs, storage, handling 
and operator error as causes, paving the way for collect-
ing confirmatory evidence on parasite related issues. 
Therefore, molecular characterization of the P. falcipa-
rum is highly recommended to examine parasite charac-
teristics as causes of false negative results.
Important lessons have been learnt from the inci-
dence under investigation, such that vigilance need to 
be heightened in monitoring the efficacy of RDTs regu-
larly and that intermittent random check-ups must be 
conducted to cross-check the RDTs against other diag-
nostic tools such as light microscopy or PCR if feasible. 
Moreover, it is imperative that international guidance be 
produced on monitoring high false negativity result as it 
may have public health implication at local, regional and 
international levels.
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